In the and of the article says: "Now, throughout this entire process, you still legally own your shares in the company (should you choose not to sell them). However, delisting is generally regarded as the first step toward potential Chapter 11 bankruptcy. Should one of your stocks be delisted from a major exchange, it would be prudent to review carefully the reasons for its removal and the impact it will have on you as an investor - as you may not want to continue holding the stock."
And that is the PSUNQ story
I have read the other thread about delisting. It is kind of ambiguous. Do they mean PSUN will be delisted, but PSUNQ will continue to trade?
No, I considering to unload whatever value left till 15th. Do I missing anything?
"The Company's common stock was suspended on April 14, 2016 and has not traded on Nasdaq since that time. On July 5, 2016, Nasdaq filed a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting will become effective on July 15, 2016, ten days after the filing of the Form 25."
Doubt, it will going to happen. Dilip will bring another his puppet. I'm not expecting much changes here, unless the rising Taro's SP will align with his interests.
I assume not all investors understated Taro's situation. They may think "Taro had great financial results with current CEO and when he is gone the result wouldn't be as good". I'm pretty sure the new CEO will be also dancing according to Sun's interests. So, I do not expect any material change. The volume intensifies with over 216K so far and almost $5 drop. Expect to recover by EOD.
Before was CFO, now CEO - just to keep investors scary about uncertain future of the co?
Pretty sure Dilip will bring someone else from his team....
Looks like it also heavy manipulated to allow Taro (or someone else) to buy more shares at cheaper price. On every new 10K buy demand comes 11K sell, usually Taro SP would go thru the roof with such demand. Last 30 trading days traded 9,36M shares with average volume of 333K a day, previous 30 days 5.1M with average volume of 177K, totaly 14.7M or more then whole minority holding. Periodically traded a big blocks of 15-25K shares, just less then 50 reporting institutions hold more then this amount, but who would sell big porsion of the holding in 1 block?....
Taro could buy both unitswith cash or any of them cheaper then Valeant paid in 2013. The question does it worth it?
The two businesses could fetch as much as $500 million and attract interest from other pharmaceutical companies, the people said, asking not to be identified because the deliberations are private. The sale process could start as early as this week, they said.
Representatives at Valeant and Morgan Stanley declined to comment.
Valeant shares rose 1.1 percent to $24.04 at 9:41 a.m. in New York. The stock has slumped 76 percent this year, valuing the company at $8.2 billion.
Valeant bought the maker of prescription skin-care products Obagi in 2013 for about $418 million. Later that year, it agreed to buy Solta for about $250 million. Solta designs, makes and sells medical devices for aesthetic applications such as wrinkle and acne treatments.
are they going discuss it w/o actual numbers? "announced that it plans to host a conference call and live webcast on June 7, 2016 to discuss first quarter 2016 financial
can they provide some info in the event: "NovaBiotics has been selected to present exciting new data on antibiotic resistance breaking at ASM MICROBE/ICAAC 2016 in a talk and poster format in BCEC Meeting Room 161 between 1445 and 1715 on June 17th in Boston."
Read the transcript. I can't get how all those useless analysts concentrate on not significant issues and not the questions we talked here for some time and you asked on cc. At least, it is not on this MB only but it been herd by many other people. Well done.
Agree too. Also, YOY revenue increase 8.6%, operational income 18%!.
And that sound funny but following sentence "Nevertheless, we remain cautiously optimistic about our medium and long-term growth and remain focused on strengthening our R&D pipeline and other initiatives that continue to keep us well positioned in the market.” is the most optimistic in the last 3 years.!
Looked into Iszo holding:
1. Sold out most of the portfolio value (and 7 of 12 stocks). Added 2 new.
2. The whole portfolio value now is a fraction of the Taro stake he had.
Strange , he had ~90% in cash by march 31.